🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

9 recruiting trials

for CLDN18.2 Positive Solid Tumors

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors NCT07483554Phase 21 site📍 Hangzhou Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI343,Gemcitabine, Albumin-bound Paclitaxel Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) NCT07432295Phase 26 sites📍 Goodyear📍 Duarte📍 Boston I-Mab Biopharma US Limited · Tests: Givastomig, Nivolumab, 5Fluorouracil, Leucovorin, Oxaliplatin A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors NCT05205850Phase 1, Phase 22 sites📍 Shanghai📍 Hangzhou RemeGen Co., Ltd. · Tests: RC118-ADC Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors NCT06084286Phase 11 site📍 Chengdu Sichuan University · Tests: Dual-targeting CLDN18.2 and PD-L1 CAR-T cells SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor NCT06350006Phase 11 site📍 Guangzhou Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-A1904; Adebrelimab, SHR-A1904; CAPOX; Adebrelimab SG1906 for CLDN18.2-Positive Solid Tumors NCT05857332Phase 19 sites📍 Beijing📍 Xiamen📍 Guangzhou Hangzhou Sumgen Biotech Co., Ltd. · Tests: SG1906 A IIT Study of 177Lu-DOTA-SNA040 NCT07595237EARLY Phase 11 site📍 Shanghai SmartNuclide Biopharma · Tests: 177Lu-DOTA-SNA040 A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors NCT07460375Phase 1, Phase 28 sites📍 Boston📍 Lake Success📍 Charleston LigaChem Biosciences, Inc. · Tests: LCB02A An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors NCT07680257EARLY Phase 11 site📍 Hefei Celest Therapeutics (Shanghai) Co., Ltd. · Tests: SUV2208A cell injection, SUV2208A, SUV2208A
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy